 Rx Pharmaceuticals Inc NASDAQ: NRXP shares are up around 25 during mid-day session on mild volume, in reaction to safety update on Zyesami aviptadil ACTIV-3 Critical Care Phase 3 study in COVID-19 patients. The NIH-sponsored trials Data Safety Monitoring Board found no new safety concerns and recommended continued enrollment. 